Breast Cancer Coverage from Every Angle

Androgen Receptor–Targeted Treatment in Triple-Negative Breast Cancer

By: Sarah Campen, PharmD
Posted: Monday, March 26, 2018

In reportedly the largest prospective trial to date of an androgen receptor (AR)-targeted treatment of advanced triple-negative breast cancer, enzalutamide showed a clinical benefit, according to a study reported in the Journal of Clinical Oncology, and adverse events were consistent with the known safety profile of this agent.

“Data from this phase II study in a group of patients with AR-positive [triple-negative breast cancer] support and build upon the findings from others that there seems to exist a subset of patients with androgen-driven [triple-negative breast cancer] who may benefit from an AR-targeted agent,” stated Tiffany A. Traina, MD, of Memorial Sloan Kettering Cancer Center, and colleagues.

From 45 sites in 7 countries, 118 patients with triple-negative breast cancer and an AR-positive tumor (nuclear AR staining > 0%) received enzalutamide at 160 mg daily until disease progression. An evaluable subgroup of 78 patients had tumors expressing ≥ 10% nuclear AR.

The median duration of treatment for all patients was 8.1 weeks. The study found the clinical benefit rate at 16 weeks was higher in the evaluable subgroup (33%) than in the intent-to-treat population (25%). The median overall survival was 17.6 months in the evaluable subgroup and 12.7 months in the intent-to-treat population, and the median progression-free survival was 3.3 months and 2.9 months, respectively. As for toxicity, fatigue (3.4%) was the only treatment-related grade ≥ 3 adverse event occurring in more than 2% of patients.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.